Research on methylation of FHIT,hMLH1,p16,RAR-beta,Reprimo and TIMP3 genes in gastric cancer patients
10.11904/j.issn.1002-3070.2019.01.002
- VernacularTitle:胃癌患者FHIT、hMLH1 、p16 、RAR-beta、Reprimo和TIMP3基因的甲基化研究
- Author:
Yuxian BAI
1
;
Zhongjuan MA
;
Yingling SU
;
Anguo MU
;
Rui XIE
Author Information
1. 哈尔滨医科大学附属肿瘤医院消化肿瘤内科(哈尔滨 150081
- Keywords:
Gastric cancer;
Bisulfite sequencing PCR method;
Methylation;
Reprimo gene
- From:
Practical Oncology Journal
2019;33(1):8-13
- CountryChina
- Language:Chinese
-
Abstract:
Objective The aim of this study was to investigate the methylation status of fragile histidine triad( FHIT) gene, human mutl homolog 1(hMLH1)gene,p16 gene,retinoic acid receptor beta( RAR-beta) gene,Reprimo gene and tissue inhibitor of metalloproteinase 3 ( Timp3) gene in gastric cancer and corresponding paracancerous tissues. Methods The methylation levels of FHIT,hMLH1,p16,RAR-beta,Reprimo and TIMP3 genes in 42 clinically resected gastric cancer specimens and 42 corresponding paracancerous tissues were detected by sodium bisulfite sequencing. Results The average methylation rates of the genes in gastric cancer and corresponding paracancerous tissues were:FHIT(1. 50% ,1. 36% ),hMLH1(4. 77% ,0. 48% ),p16(9. 63% ,10. 36% ), RAR-beta(4. 75% ,4. 17% ),Reprimo(9. 71% ,3. 76% )and TIMP3 genes(18. 34% ,14. 06% ). Compared with the paracancerous control group,the average methylation rate of Reprimo gene was only statistically different in gastric cancer patients(P=0. 00787). The difference in methylation rate of Reprimo gene promoter in gastric cancer patients with the degree of tissue differentiation was sta-tistically significant(P<0. 05). Conclusion There has methylation in the cytosine guanidine dinucleotide island of the Reprimo gene promoter region in gastric cancer. The high methylation rate of the Reprimo gene can be used as a potential biomarker for gastric cancer to detect the early stage of gastric cancer.
